FATE THERAPEUTICS INC — Form 8-K
Filed August 13, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 68/100
What the filing says
Fate Therapeutics dosed the first patient in RECLAIM-LN, a Phase 2 potentially registrational trial of FT819 (iPSC-derived off-the-shelf CAR T) for lupus nephritis, with outpatient same-day discharge. The company also received FDA IND clearance for FT839 (dual CD19/CD38 CAR T) for autoimmune diseases. Q2 2026 cash position is $153.8M (down $21M from Q1); company projects runway into 2028. Net loss was $30.2M for Q2 2026 versus $34.1M in Q2 2025.
Why this rating
Major clinical milestone (first patient in registrational trial) is meaningful for ~$113M company. Pipeline advancing with multiple programs. Cash runway extends 18+ months. Operational progress de-risks near-term, but execution risk remains high for early-stage biotech.
See more from August 13, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.